When Will MicroTech Medical (Hangzhou) Co., Ltd. (HKG:2235) Become Profitable?

With the business potentially at an important milestone, we thought we'd take a closer look at MicroTech Medical (Hangzhou) Co., Ltd.'s (HKG:2235) future prospects. MicroTech Medical (Hangzhou) Co., Ltd. provides diabetes management, diabetes treatment, and diabetes monitoring medical devices in China and internationally. On 31 December 2024, the HK$3.6b market-cap company posted a loss of CN¥63m for its most recent financial year. The most pressing concern for investors is MicroTech Medical (Hangzhou)'s path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Consensus from 2 of the Hong Kong Medical Equipment analysts is that MicroTech Medical (Hangzhou) is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of CN¥16m in 2026. The company is therefore projected to breakeven just over a year from now. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 93% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

We're not going to go through company-specific developments for MicroTech Medical (Hangzhou) given that this is a high-level summary, but, take into account that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for MicroTech Medical (Hangzhou)

Before we wrap up, there’s one aspect worth mentioning. MicroTech Medical (Hangzhou) currently has no debt on its balance sheet, which is quite unusual for a cash-burning growth company, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of MicroTech Medical (Hangzhou) which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at MicroTech Medical (Hangzhou), take a look at MicroTech Medical (Hangzhou)'s company page on Simply Wall St. We've also put together a list of relevant aspects you should further examine:

1. Valuation: What is MicroTech Medical (Hangzhou) worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether MicroTech Medical (Hangzhou) is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on MicroTech Medical (Hangzhou)’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.